Stent Implantation

NEW YORK — In this presentation from OSN New York, Thomas W. Samuelson, MD, of Minnesota Eye Consultants, uses surgical footage to demonstrate implantation of the Xen gel stent for the treatment of glaucoma.

WASHINGTON — In patients with severely calcified coronary lesions eligible for either treatment, orbital atherectomy did not improve clinical or imaging outcomes compared with conventional balloon angioplasty, researchers reported.

Despite better representation in drug trials in the past few decades, women continue to be underrepresented in trials assessing high-risk medical implantation devices, according to a systematic review published in JAMA Internal Medicine.

SAN FRANCISCO — In patients with ACS, stopping aspirin for ticagrelor monotherapy within 1 month of receiving a drug-eluting stent did not increase adverse CV and bleeding events compared with 12 months of dual antiplatelet therapy.

In this exclusive surgical video for Healio/OSN, I. Paul Singh, MD, uses the iStent infinite to inject three heparin-coated titanium stents into the anterior chamber of an eye with uncontrolled primary open-angle glaucoma.

Balloon angioplasty and stent implantation procedures in the early postoperative period after congenital heart surgery are overall relatively safe and effective, data from a retrospective, single-center study show.

In patients with femoropopliteal artery disease amenable to treatment with drug-coated balloons or bare-metal stents, DCBs appear to be the better option, according to an analysis presented at VIVA 22.

In a new analysis from AFIRE, among patients with atrial fibrillation and stable CAD with prior coronary stenting, rivaroxaban monotherapy was superior to rivaroxaban plus an antiplatelet agent in both efficacy and safety.

In patients with complex peripheral artery disease, a drug-coated balloon performed similarly to how it did in the general PAD population, according to new data from the IN.PACT Global registry.

A drug-eluting stent outperformed bare-metal stents for treatment of patients with lesions in the superficial femoral and proximal popliteal arteries, according to results of the EMINENT trial presented at VIVA 21.